Skip to site menu Skip to page content

Daily Newsletter

17 December 2024

Daily Newsletter

17 December 2024

Adagio Medical announces Todd Usen as new CEO and director

Olav Bergheim has stepped down from his roles as CEO and chairperson but will continue to serve as an adviser for a year.

gullapalli December 17 2024

Adagio Medical has announced the appointment of Todd Usen as the company’s new chief executive officer (CEO) and director, and Orly Mishan as the board of directors’ chairperson.

Both transitions are effective from 13 December this year.

The company's founder, Olav Bergheim, has stepped down from his roles as CEO and chairperson but will continue to serve as an adviser for a year.

Before his appointment at Adagio, Usen worked as Minerva Surgical’s president and CEO, where he led the company through a successful restructuring and significant growth.

He also held the position of CEO at Activ Surgical, where he oversaw Food and Drug Administration (FDA) / CE clearance of surgical imaging technology and spearheaded fundraising efforts that amassed more than $92m.

Usen's experience extends to leading more than $2bn business as president of the Medical Systems Group at Olympus Corporation, where he was instrumental in strategic expansion, operational restructuring, and mergers and acquisitions.

His career also encompasses executive roles at Boston Scientific Corporation and Smith and Nephew.

At present, Usen serves as Rob Surgical’s executive chairman, NeoPredics’ chairman, and Alesi Surgical’s director.

Usen said: “I’m thrilled to join Adagio at this important junction in the company’s history, supporting initial commercial efforts in Europe, and the FULCRUM-VT trial enrolment in the US.

“With a growing body of evidence demonstrating both the safety and effectiveness of Adagio’s ultra-low temperature cryoablation technology and marked enthusiasm of users in both Europe and North America, I believe that Adagio’s VT Cryoablation System with vCLAS catheter will become the future standard of care for treatment of patients with ventricular tachycardia.”

Based in California, US, Adagio is a medical device company that specialises in developing cryoablation technologies aimed at creating treatments for various cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, ventricular tachycardia, and atrial flutter.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close